Fonte foto: http://www.YouAndLungCancer.com
A Multicenter Study of Thromboembolic Events Among Patients Diagnosed With ROS1-rearranged Non-Small Cell Lung Cancer
Marliese Alexander, Nick Pavlakis, Thomas John et Al.
Lung Cancer 2020 Apr;142:34-40. doi: 10.1016/j.lungcan.2020.01.017. Epub 2020 Jan 22.
CARDIONCOLOGY.ORG ABSTRACT:
This article describes the longitudinal thromboembolism (TE) risk in ROS1 rearranged non-small cell lung cancer (NSCLC).
Data from 42 patients revealed that there is sustained TE risk that is independent of therapeutic strategy.
The authors recommend further validation of the high incidence of PE, concurrent TE, and recurrent TE found in this study.